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Between January 1, 1992, and January 23, 1996, 111 consecutive patients 
with severe left ventricular dysfunction underwent isolated coronary artery 
bypass grafting. The ejection fraction in these patients ranged from 10% to 
34% (mean 27.9% _ 5.4%); in 18 patients the value was less than 20%. The 
high operative mortality rate (7.6% in Society of Thoracic Surgeons 
database) in this group of patients at high risk was targeted for reduction 
by provision of, in addition to the usual inotropic support, progressively 
more intensive metabolic and mechanical support. The metabolic support 
consisted of triiodothyronine; glucose, insulin, and potassium; aspartate/ 
glutamate in the cardioplegic solution; and warm-cold-warm/antegrade- 
retrograde-antegrade cardioplegia. Mechanical support included liberal 
use of the intraaortic balloon pump, use of a new occlusive retrograde 
cardioplegia catheter, ultrafiltration to remove myocardial depressant 
factors, and, finally, delayed sternal closure. The operative mortality rate 
was 1.8% (2/111). Complications included reoperation because of bleeding 
(3.6%, 4/111), mediastinitis (1.8%, 2/111), and stroke (0.9%, 1/111) and 
there were no occurrences of new postoperative acute renal failure (0.0%, 
0/111). The intensive care unit stay was 2.2 - 0.9 days with a length of stay 
in the hospital of 13.7 -+ 22.1 days. These techniques done before operation, 
intraoperatively, and postoperatively optimize the milieu of the depressed 
left ventricle by maximizing perioperative high-energy phosphate bonds; 
increasing the effectiveness of inotropic agents; unloading the left ventricle 
by chemical, metabolic, and mechanical support; and removing known 
myocardial depressant factors, which reduced the operative mortality rate 
to 1.8% compared with 7.6% as reported in the Society of Thoracic 
Surgeons' database. (J Thorac Cardiovasc Surg 1997;113:655-66) 
]n patients with severe left ventricular failure 
]caused by ischemic ardiomyopathy, the superior 
long-term survival treatment has been clearly shown 
to be coronary artery bypass grafting (CABG). 1-4 
Christakis and associates 4 in a recent article clearly 
delineated the peculiar operative risk factors found 
in this selected group of patients as compared with 
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those in patients at large undergoing coronary artery 
bypass and noted that urgency of operation, reop- 
eration, sex, myocardial protection, and age were 
the greatest predictors of operative death. Of these, 
only myocardial protection and to a lesser extent 
urgency of operation, which itself is often dictated 
by the deteriorating clinical situation of the patient, 
can be altered. This group of patients with severe 
left ventricular failure, however, has a high periop- 
erative mortality rate as noted by the Society of 
Thoracic Surgeons (STS) database, which reported 
a 7.6% mortality rate in 26,661 patients from the 
years 1992 to 1995. Although operation bestows the 
best long-term survival benefit in this group of 
patients as compared with medical therapy, early 
operative mortality in one major review paper was 
5% to 25%. 3 
During a 4-year period from January 1, 1992, to 
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Table I. Mechanical and metabolic support for patients with low EF 
1992-1996 Usage 1995 Usage 
Mechanical 
IABP 32.4% (36/111) 30.0% (12/40) 
Ultrafiltration during bypass 5&7% (63/111) 100.0% (40/40) 
Occlusive retrograde balloon catheter 69.3% (77/111) 100.0% (40/40) 
Delayed sternal closure 2.7% (3/111) 0.0% (0/40) 
Metabolic 
T3 49.5% (55/111) 100.0% (40/40) 
GIK 50.5% (56/111) 100.0% (40/40) 
Aspartate/glutamate 100.0% (111/111) 100.0% (40/40) 
Warm-cold-warm/ante-retro-ante c rdioplegia 100.0% (111/111) 100.0% (40/40) 
January 23, 1996, we prospectively analyzed results 
in a consecutive series of patients with severe left 
ventricular dysfunction with a mean left ventricular 
ejection fraction (EF) of 27.9% _+ 5.4% (range 10% 
to 35%). An integrated approach extending from 
the immediate preoperative period to 24 hours after 
operation was progressively instituted to maximize 
the milieu preoperatively, intraoperatively, and then 
postoperatively with respect to increasing myocar- 
dial energy bonds, continuously unloading the left 
ventricle, and directly removing myocardial depres- 
sant factors (Table I). This series consisted of 111 
consecutive patients operated on in one institution 
by five surgeons but with use of the standardized 
technique of a single surgeon (G. E. C.). 
Methods 
Between January 1, 1992, and January 23, 1996, 1913 
patients underwent isolated CABG at Wilkes-Barre Gen- 
eral Hospital. A subgroup of 111 patients had an EF of 
35% or less with a range of 10% to 35%. Data for these 
111 patients were prospectively and consecutively gath- 
ered for analysis of operative mortality and morbidity. All 
other patients undergoing CABG with additional proce- 
dures such as valve and aneurysm procedures were ex- 
cluded from the study. 
For the sake of the analysis we compared ata from our 
group with data from the STS national database during 
the same period (1992 through 1995) (all data from the 
STS obtained through the national database with permis- 
sion). The STS study group had an EF of 10% to 35% with 
a mean EF of 26.3% -+ 7.2% (Wilkes-Barre General 
Hospital 27.9% -+ 5.4%). 
Table II is a list of clinical variables analyzed for this 
study and compared with those of the STS database. 
Diabetes mellitus included insulin-dependent diabetes 
and non-insulin-dependent diabetes. Acute myocardial 
infarction was defined as an event that occurred in the 
previous 30 days before the operation including both 
transmural and subendocardial infarcts. A perioperative 
myocardial infarct was defined as a new Q wave on the 
postoperative electrocardiogram or creatine kinase MB 
levels greater than 10% or total quantitative number 
greater than 1000. Renal failure, either chronic or acute, 
was defined as a creatinine concentration greater than 1.5 
mg/dl. The mortality rate included deaths within a 30-day 
period after operation that occurred in or out of the 
hospital. The EF was calculated by the cardiologist via a 
30-degree right anterior oblique projection on cineradiog- 
raphy. When appropriate, thallium stress testing with 
resting reinjection with the use of single-photon emission 
computed tomography (SPECT) is our standard thallium 
preoperative test. The dobutamine stress test was done 
with the aid of esophageal ultrasonography and local 
anesthesia with use of a low-dose regimen of dobutamine 
in doses of 5 and 10 /zg/kg per minute to assess wall 
segment motion. Definition of the operation as elective or 
emergency was determined by the operating surgeon, but 
emergency operations generally included those done less 
than 24 hours after the cardiac atheterization r during a 
clearly deteriorating clinical situation. Cardiogenic shock 
was defined as persistent hypotension with systolic blood 
pressure lower than 100 mm Hg with a cardiac index less 
than 2.0 L/m a and generally necessitated the use of an 
intraaortic balloon pump (IABP) to stabilize the patient's 
condition on the way to the operating room. Coronary 
artery anatomy was considered significantly compromised 
when greater than 70% luminal narrowing occurred in a 
major vessel, except in the left main artery where narrow- 
ing of 50% was considered significant. Preoperative 
rhythm disturbances were considered significant if they 
were ventricular in origin and noted by the surgeon. 
The paucity of deaths (2) in this series precluded any 
statistical analysis of various risk factors or treatment 
modalities as to their effect on death. All data were 
collected prospectively by the perfusionists, nurse practi- 
tioner, and physicians' assistant and collated on Patient 
Profiles by Aspen computer program software with an 
IBM 486 computer. Statistical proportions were com- 
pared for the different reatment groups for each clinical 
variable with either a two-sided )(2 test or a two-sided 
independent-sample Student,s t test; p values were con- 
sidered significant if less than 0.05. Values given herein 
after the plus or minus sign are the standard eviation. 
Surgical technique. Patients were brought o the oper- 
ating room where lines were placed after institution of 
general endotracheat high-dose narcotic anesthesia. One 
gram of methylprednisolone was given intravenously at 
induction of anesthesia. A Swan-Ganz catheter (Baxter 
Healthcare Corp., Edwards Division, Santa Ana, Calif.) 
was inserted in each case. The IABP, if needed, was 
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Table II. Preoperative data 
Study group STS control group 
Category (111 patients) (26,661 patients) p Value 
EF (%) 27.9 +- 5.4 26.3 ± 7.2 0.06 
Age (yr) 62.6 + 9.9 65.1 -+ 10.2 0.07 
Sex 
Male 79.2% (88/111) 76.8% (2,049/26,661) 0.55 
Female 20.7% (23/111) 23.1% (6,170/26,661) 0.55 
Diabetes 44.1% (49/111) 35.9% (9,575/26,661) 0.07 
Left main disease 38.7% (43/111) 21.8% (5,815/26,661) 0.00" 
Acute MI 34.2% (38/111) 32.0% (8,557/26,661) 0.63 
COPD 33.3% (37/111) 20.2% (5,392/26,661) 0.00" 
Acute/chronic renal failure 10.8% (12/111) 6.6% (1,774/26,661) 0.08 
PVD 12.6% (1.4/111) 10.7% (2,864/26,661) 0.53 
Obesity 35.1% (39/111) 11.7% (3,143/26,661) 0.00' 
Repeat operation 2.7% (3/111) 12.9% (3,454/26,661) 0.00" 
Arrhythmia 17.1% (19/111) 19.9% (5,313/26,661) 0.46 
Emergency operation 10.8% (12/111) 11.6% (3,102/26,661) 0.79 
CVA 5.4% (6/111) 7.2% (1,929/26,661) 0.46 
Congestive heart failure 29.7% (33/111) 25.1% (6,695/26,661) 0.26 
Angina 
Stable 5.4% (6/111) 16.0% (4,286/26,661) 0.00" 
Unstable 44.1% (49/111) 65.7% (17,531/26,661) 0.00" 
No angina 50.5% (56/111) 18.3% (4,844/26,661) 0.00" 
M1, Myocardial infarction; COPD, chronic obstructive pulmonary disease; PVD, pulmonary vascular disease; CVA, cerebrovascular accident. 
*Statistically significant difference. 
generally placed before operation in the catheterization 
laboratory or after the institution of general anesthesia 
and placement of the Swan-Ganz catheter. Intravenous 
administration of nitroglycerin was started immediately 
after the patient was brought o the operating room and 
was continued for 24 hours after operation. If the first 
measured cardiac index was less than 2.0 L/m 2 then 
inotropes, unloading drugs, and IABP support were insti- 
tuted in a progressive fashion. Initially drugs such as 
dobutamine, 1 to 5 /xg/kg, were given, followed by milri- 
none or amrinone if the systemic vascular resistance or the 
pulmonary artery pressure was significantly elevated. If 
the index was still less than 2 L/m 2, then epinephrine 
along with IABP support was added. If the EF was less 
than 20% before operation serious consideration was 
always given to insertion of an IABP before operation. 
Triiodothyronine (T3) was given shortly after the pa- 
tient was brought o the operating room in a 0.4/xg/kg per 
minute dose via an intravenous bolus over 10 minutes 
followed by a second dose of 0.8/xg/kg approximately 10 
minutes before the end of bypass and finally a third dose 
of 0.4 txg/kg divided over 24 hours and given continuously 
during the next day. Glucose, insulin, and potassium 
(GIK) were concomitantly used with T 3 with administra- 
tion started on entry of the patient o the operating room 
at a 1 ml/kg per hour rate with 30% glucose, 200 units of 
insulin, and 40 mEq of potassium. Careful monitoring of 
the glucose level was done in all patients every 20 minutes 
in the operating room and then every hour in the intensive 
care unit for 24 hours. After application of the crossclamp 
the rate of GIK solution administration was reduced to 1/3 
ml/kg and maintained for 24 hours. 
Cardiopulmonary b pass was instituted with use of an 
ascending aortic cannula followed by a two-stage venous 
cannula, Cardioplegic solution was given via a multitiered 
retrograde catheter (Research Medical, Midvale, Utah) 
placed into the coronary sinus before bypass and an aortic 
cardioplegia venting cannula for the antegrade portion of 
the cardioplegia. Venting was done primarily via the aorta 
and if necessary the pulmonary artery. Nifedipine, 10/zg 
sublingually, was prophylactically given to all patients at 
the beginning of the operation, again just before removal 
of the crossclamp, and at any time during the operative 
procedure when there were significant ST changes. The 
cardiopulmonary b pass machine was primed with albu.- 
min solution and run at 2.4 L/min 2. The internal thoracic 
artery was taken down with cautery before bypass using 
neither bone wax nor cautery on the sternum. After the 
crossclamp was applied, the patient was given standard 
Buckberg blood cardioplegic solution with an initial dose 
of warm antegrade solution followed by near continuous 
cold retrograde infusion and concluding with a warm 
retrograde/antegrade infusion. During the cold retrograde 
portion of the cardioplegia the solution was infused 
continuously with only short pauses during performance 
of the distal anastomosis. In addition, the right coronary 
graft was completed first and from then on cardioplegic 
solution was given continuously in an antegrade fashion 
into the right graft while simultaneously retrograde infu- 
sion was done into the coronary sinus. Other grafts were 
infused at the discretion of the surgeon. The systemic 
perfusion temperature was controlled at 34 ° C and no ice, 
slush, or water was used in the pericardium during the 
procedure. Retrograde cardioplegic solution administra- 
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Table I lL  Operative dam 
Variable Study group STS p Value 
Right coronary bypass 90.0% (100/111) 86.6 (23,105/26,661) 0,29 
Emergency operation 10.8% (12/111) 9.1% (2,451/26,661) 0.56 
Reoperation 2.7% (3/111) 12.9% (3,454/26,661) 0.00" 
No. of distal anastomoses 
Mean 3.5 + 0.8 3.5 _+ 1.1 1.0 
Range 1-9 (110 > 2) N/A 
ITA usage 83.7% (93/111) 54.5% (14,546/26,661) 0.00" 
Bilateral ITAs 18.9% (21/111) 2.0% (544/26,661) 0.00" 
Cardiopulmonary b pass 
Crossclamp time (min) 58.5 + 23.6 63.0 _+ 29.5 0.14 
Cardiopulmonary b pass time (min) 107.6 _+ 44.3 109.1 _+ 45.2 0.74 
Time cardioplegia running during crossclamp (%) 70.1 N/A 
Perfusate temperature (°C) 34 _+ 1 29.5 _+ 3.1 0.00* 
Inotropes 50.4% (56/111) 59.6% (15,903/26,661) 0.04* 
IABP 
Preoperative 20.7% (23/111) 16.3% (4,360/26,661) 0.21 
Intraoperative 9.9% (11/111) 8.4% (2,262/26,661) 0.59 
Retrograde catheter perforations 0.0% (0/111) N/A 
N/A, Not available; ITA, internal thoracic artery. 
*Statistically significant difference. 
Table IV. Postoperative complications inpatients with low EF 
Study group STS control group 
Category (111 patients) (26, 661 patients) p Value 
Operative mortality 1.8% (2/111) 7.6% (2,035/26,661) 0:02" 
Operative mortality without reoperations 0.9% (1/108) 6.7% (1,557/23,207) 0.01" 
Reoperation because of bleeding 3.6% (4/111) 2.9% (788/26,661) 0.69 
Deep sternal wound infection 1.8% (2/111) 0.8% (213/26,661) 0.24 
Stroke 0.9% (1/111) 2.2% (3,964/26,661) 0.00" 
Renal failure 0.0% (0/111) 4.5% (1,200/26,661) 0.02* 
ICU length of stay (days) 2.2 + 0.9 N/A 
Postop. length of stay (days) 13.7 _+ 22.1 10.2 _+ 16.7 0.02* 
ICU, Intensive care unit; N/A, not available. 
*Statistically significant difference. 
tion pressure was maintained at less than 40 mm Hg with 
a flow rate ranging from 100 to 280 ml/min. 
After the completion of all distal anastomoses the 
patient was warmed systemically to 37°C while warm 
cardioplegic solution followed by warm blood was given by 
the retrograde followed by the antegrade method. The 
crossclamp was then removed. In reoperations all proxi- 
mal grafts were placed during the initial crossclamp 
period. Ultrafiltration was used immediately after the 
institution of bypass with an Amicon, Minn Tech, or, most 
recently, Research Medical filter and stopped at the 
termination of bypass. In patients who had renal failure 
before the operation, continuous dialysis was also done 
with the ultrafiltration using counter current dialysate to 
allow both ultrafiltration and dialysis simultaneously. Ad- 
ministration of T 3 (0.4/xg/kg) and GIK was then contin- 
ued for 24 hours. Finally, if myocardial edema precluded 
closure of the chest, the chest was left open with either 
closing of the skin or use of a sterile Steri-drape dressing, 
and at the earliest possible time, usually the second day 
after the operation, an omental transfer was done fol- 
lowed by closure of the sternum. Atrial-ventricular pacing 
wires were routinely inserted. 
Results 
Data were analyzed from 111 consecutive patients 
with a mean age of 62.6 +_ 9.9 years (range 36 to 83 
years) (Tables II, I I I ,  and IV). There were 88 male 
and 23 female patients. Preoperative risks included 
diabetes in 44.1% (49/111), left main disease in 
38.7% (43/111), acute myocardial infarction in 
34.2% (38/111), chronic obstructive pulmonary dis- 
ease in 33.3% (37/111), and acute or chronic renal 
failure in 10.8% (12/111). Emergency operat ion was 
necessary in 10.8% (12/111) of the patients. The 
internal thoracic artery was used in 83.7% (93/111) 
and bilateral thoracic arteries in 18.9% (21/111). 
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The mean number of grafts placed was 3.5 _+ 0.8 per 
patient. An IABP was placed prophylactically in
20.7% (23/111) of patients in this series. In 17 of the 
23 in whom an IABP was placed prophylactically, 
insertion was done in the catheterization laboratory. 
Cardiogenic shock was present in 6.3% (7/111). 
The operative mortality rate was 1.8% (2/111). 
One patient (EF 32%) died of ventricular tachycar- 
dia and the second (EF 34%) of progressive renal 
failure early in the series. Morbidity consisted of 
bleeding that necessitated reoperation in 3.6% (4/ 
111), mediastinitis in 1.8% (2/111), and stroke in 
0.9% (1/111). No episodes (0.0%, 0/111) of new 
postoperative acute renal failure occurred. The 
length of stay in the intensive care unit was 2.2 _+ 0.9 
days with a total hospital stay of 13.7 +_ 22.7 days. 
There were no significant complications noted from 
the T 3 infusion or the GIK infusion. There were 
0.0% (0/111) perforations of the coronary sinus with 
use of the new multitiered retrograde coronary sinus 
catheter and there were no complications related 
directly to the IABP or to the delayed sternal 
closure. Finally, ultrafiltration was done without any 
difficulty and long-term dialysis was reinstituted on 
the second postoperative day or as needed. 
Discussion 
Selection of patients. Primarily, patients who had 
well-defined anatomic targets were selected for op- 
eration (Table V). Two or more major vessels 
supplying significant portions of viable muscle had 
to be present. In the most severe cases (EF less than 
20%) good targets outweighed a poor EF especially 
if the poor EF was thought o be caused by severe 
global ischemia, that is, left main coronary artery 
obstruction. Other factors included positive findings 
on a thallium stress reinjection SPECT study and, 
most recently, a positive result on an esophageal 
dobutamine chocardiographic stress test. s-l° Con- 
sidering that 50.5% (56/111) of the patients had no 
angina, decreased left ventricular function without 
angina was not a contraindication toour offering the 
patient an operation. Indeed, if other factors were 
favorable, we were inclined to offer coronary bypass 
to patients with symptoms of congestive heart fail- 
ure, as have others. I' 2, 4, 11 
In the absence of angina and when the patient has 
a very low EF one should consider performance of a 
stress redistribution thallium or dobutamine stress 
test to discern viable functioning or hibernating 
myocardium. 7-9 Thallium SPECT stress reinfusion 
testing was done in 25 of the 111 patients in whom 
Table V. Ideal criteria for operation with low EF 
At least two grafts possible 
Good anatomic targets 
Left main disease 
Nonemergency operation 
Can use an IABP 
Age <70 yr 
Positive result on thallium stress test (SPECT) with reperfusion 
Positive dobutamine stress test result 
we were concerned about adequate viable myocar- 
dium. One should not deny surgical therapy simply 
on the basis of the presence of an akinetic segment 
that has a nonfilling defect on the reinjection phase 
of thallium SPECT scanning (the so-called fixed 
defect). Zarich and colleagues 7 eloquently demon- 
strated that 43% of fixed defects on thallium rein- 
jection scanning showed improved wall motion after 
operation, with improvement either to normal ki- 
netic motion or hypokinetic motion. Alfieri and 
coworkers s clarified the results of dobutamine stress 
tests on fixed akinetic segments by showing 98.8% 
(89/90) of akinetic segments normalized after oper- 
ation if wall motion improved on the dobutamine 
echocardiogram. The functional testing ability of the 
dobutamine chocardiogram provides information 
on wall motion reversibility in addition to determin- 
ing wall motion viability. Although positive mission 
tomography scanning with F18 glucose is unques- 
tionably the gold standard for determining viable 
myocardium, even it does not dictate whether viable 
muscle is contracting muscle. 8
Rationale for the metabolic and mechanical ad- 
juncts. A successful surgical procedure on severely 
dysfunctional myocardium ust rely on adjuncts not 
necessary in routine CAGB operations such as those 
in patients with EFs greater than 35%. The chroni- 
cally ischemic heart is definitely at risk for low 
output syndrome in the immediate postoperative 
period. Cardiopulmonary bypass and cardioplegia, 
which are necessary for the performance of precise 
coronary bypass grafting, are in themselves harmful 
from a variety of aspects. 12 We chose to target hese 
harmful effects before, during, and for 24 hours after 
operation until the perioperative myocardial depres- 
sion subsides, primarily by emphasizing unloading as 
the single best physiologic alteration to improve 
cardiac performance throughout the perioperative 
period. Thus in Fig. i we compare our mean cardiac 
index with that in the study of Breisblatt and col- 
leagues, 12 reported in 1990. That group from the 
University of Pittsburgh looked at cardiac index for 
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Fig. 1. Continuous postoperative h modynamic changes (cardiac index in liters per meter squared) in 
patients undergoing CABG with decreased left ventricular function at Wilkes-Barre General Hospital 
(WBGH) (EF 27.9% - 5.4%) versus data from the University of Pittsburgh (Univ of Pitt) as reported by 
Breisblatt and colleagues 12 of patients with normal eft ventricular function (EF 58.0% - 12%). Note 
continuous improvement in cardiac index in patients operated on at Wilkes-Barre General Hospital 
throughout the perioperative p riod. 
24 hours after outine CABG in patients with an EF 
of 58.0% --- 12%. Significantly, they noted a trough 
at 4 hours that was not present in our group, as 
shown in Fig. 1. In contrast, cardiac index values in 
our patients, despite a markedly lower EF, progres- 
sively rose throughout the perioperative p riod as a 
result of deliberate attention to reducing afterload, 
which thus increased the cardiac index. 
Before the start of cardiopulmonary bypass, there 
is time in the operating room to enhance myocardial 
energy stores and reduce afterload. We began GIK 
and T 3 infusion initially at the time the patient was 
brought o the operating room even before place- 
ment of the central ines. GIK solution has been 
reported for at least 30 years to enhance myocardial 
function, reduce ischemia fter myocardial infarc- 
tion, and, more recently, improve myocardial per- 
formance after cardiac operations including 
CABG. 13-15 The salutary effects of GIK solution 
have been reported to be increased adenosine 
diphosphate and adenosine monophosphate stores 
in ischemic myocardial tissue. 14 Two independent 
controlled studies in patients undergoing cardiac 
operation reported by Coleman 15 and Girard 16 and 
their associates demonstrated an increase in the 
cardiac index at 12 and 24 hours in the GIK groups 
along with decreased inotropic support and reduced 
time to need for the IABP) 5' 16 Girard and associ- 
ates 16 further noted that GIK prevented the usual 
decrease in EF in the postoperative period by 
reducing the systemic vascular resistance and also by 
a primary myocardial effect. They also showed in the 
same double-blinded, randomized study a significant 
increase in cardiac index that was especially obvious 
in the depressed ventricle with the cardiac index 
increasing after operation by 35% with a twofold 
decrease in inotropic support and rhythm distur- 
bances. 16 Most recently, Lazar and colleagues 17in 
an animal investigation showed that GIK infusion in 
the acutely ischemic myocardium reduced tissue 
necrosis, improved wall motion scores, and reduced 
tissue acidosis in the ischemic myocardium as com- 
pared with results in control animals. We extended 
the treatment from 1 hour before operation to 24 
hours after operation because of the significant 
cost/benefit ratio without an increase in any compli- 
cations. Simultaneously with GIK therapy, we insti- 
tuted T3 therapy before operation in accordance 
with the investigations of Walker, Crawford, and 
Spinal@ swho in a study of chronic left ventricular 
dysfunction experimentally demonstrated an im- 
proved responsiveness to inotropic stimulation. 
Also, Katz and associates 19 noted that the effective- 
ness of T 3 is blunted by the presence of heparin; 
therefore, our rationale for doubling the dose of T3 
before the end of bypass is that the patient is still 
heparinized. The final dose that we use, which is 
divided over 24 hours, is delivered uring a non- 
heparinized state and thus we revert o a dose of 0.4 
p~g divided over 24 hours. DiPierro and colleagues 2° 
recently showed not only that T 3 enhanced cardiac 
output in the ischemic model by improving mechan- 
ical efficiency, but also that it did so without increas- 
ing the myocardial oxygen demand. Klemperer and 
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Fig. 2. The usual manual or self-inflating retrograde catheter (right) is often not large enough to prevent 
reflux around the balloon as pposed to the new three-tiered retrograde balloon catheter (left), which is 
longer with a larger volume to prevent reflux of cardioplegic solution and to present steal down the 
posterior descending vein. 
Table VI. Complications and costs for mechanical nd metabolic adjuncts 
Technique Complications Cost 
GIK None $16.00" 
T 3 One transient hypertensive episode $2,160.00" 
Aspartate/glutamate None $5.00* 
Warm-cold-warm/antegrade-retrograde- None No added cost 
antegrade cardioplegia 
Delayed sternal closure None $2,600.00* 
Retrograde catheter None No added cost 
Ultrafiltration None $95.00 per filter 
IABP None $650.00 per catheter 
*Average charge per patient. 
associates, al in a randomized, ouble-blind trial in 
patients with depressed left ventricular function (EF 
<40%), concluded there was a significant enhance- 
ment with T 3 of cardiac output and cardiac index 
with a decrease in the incidence of atrial fibrillation. 
Finally, Ririe and coworkers 22 demonstrated in- 
creased contractility independent of/32-adrenergic 
receptors. 
The method of antegrade and retrograde admin- 
istration of cardioplegic solution with warm induc- 
tion, followed by near-continuous cold blood infu- 
sion with warm reinfusion before unclamping is the 
Buckberg integrated cardioplegia method and pro- 
vides aspartate/glutamate to replenish high-energy 
bonds. 23 Whereas antegrade and retrograde infu- 
sions alone have advantages, the combination of 
antegrade and retrograde infusion along with the 
warm-cold-warm ethod enhances all of the posi- 
tive aspects of both techniques without detractions. 
We always administer continuous cold cardioplegic 
solution in the antegrade manner into the right 
coronary graft simultaneously with cold retrograde 
administration f solution to maximize the distribu- 
tion of the cardioplegic solution to the right side of 
the heart, which thus facilitates protection of the 
right side of the heart. 
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Table VII. Review of the recent literature for CABG 
patients with severely reduced EF since 1990 with 
mortality least to greatest 
No. of 30-Day 
Author patients Years EF mortality 
Cimochowski 111 1992-96 Mean 27.9% 1.8% 
Mickleborough 33 79 1982-93 Mean 18.0% 3.8% 
Lansman 34 42 1986-90 <20.0% 4.8% 
Elefteriades 2 83 1986-92 Mean 24.6% 8.4% 
Hammermeister 35 251 1987-90 <20.0% 9.2% 
Christakis 4 487 1982-90 <20.0% 9.8% 
Kau136 211 1987-92 <20.0% 10.0% 
Milano 3 118 1981-91 Mean 25.0% 11.0% 
Mechanical aspects were also used in our series 
including the liberal use of the IABP, ultrafiltration 
to remove myocardial depressant factors, a new 
occlusive retrograde catheter to minimize coronary 
sinus leakage, and delayed sternal closure. The use 
of the IABP in approximately 30% of the cases per 
year was relatively stable, although the last year of 
the study (1995), which had the largest number of 
patients with poor left ventricular function among 
the 4 years, saw the least use of the IABP. Although 
this was not statistically different, it does point out 
that despite increased numbers of patients the bal- 
loon pump has certainly not been used more, but 
may have been used less, and we attribute this to the 
positive inotropic and vasodilating effects of T 3 and 
GIK. In addition we, like Dietl and associates, 24 
believe that the IABP is far more effective before 
bypass than it is after bypass. In fact, Dietl and 
associates 24 reported the operative mortality rate in 
patients with prophylactic nsertion of the IABP to 
be 2.7% when it was inserted before operation 
versus 11.9% when it was inserted after operation; 
therefore we used the IABP in 20.7% of the patients 
before operation, in 9% intraoperatively, and in 0% 
after operation. 
Ultrafiltration has been used by us and others to 
remove fluid, especially in patients with congestive 
heart failure and to dialyze or remove fluid in 
patients with acute or chronic renal failure. Our 
philosophy in the past several years has been to use 
this increasingly, and currently we use it in every 
patient with a seriously decreased EF to eliminate 
proinflammatory c tokines. These vasoactive sub- 
stances are produced by the cardiopulmonary b - 
pass circuit but more recently have been shown to be 
significantly elevated before operation especially in 
those patients with poor left ventricular function. 25 
Elimination of cytokines perioperatively has actually 
been demonstrated in two series of patients. 26' 27 
Ultrafiltration may be a much simpler means of 
removing cytokines and proinflammatory proteins 
of all sorts as opposed to the use of antibodies or 
more complex chemical techniques. These proin- 
flammatory c tokines, especially tumor necrosis fac- 
tor and interleukin-6, have been specifically noted to 
cause decreased wall motion in patients after 
CABG. Deng and associates, 28 in addition, recently 
reported not only that levels of proinflammatory 
cytokines were elevated in patients with decreased 
left ventricular function, but also that there was a 
strong correlation pertaining to the use of potent 
inotropic support in the postoperative period and 
the elevation of these cytokines, especially interleu- 
kin-6. 
The method of retrograde cardioplegia was first 
proposed and used in 1955 by Gott and coworkers. 29
but has recently been revived by the experimental 
and clinical work of Buckberg, 3° among others. The 
lack of occlusion of the coronary sinus has been 
shown recently to allow a significant reflux of car- 
dioplegic solution into the right atrium, which un- 
derscores the need as noted by Menasche 31 to 
optimize retrograde delivery of cardioplegic solu- 
tion. This has further been experimentally investi- 
gated by the group at UCLA who showed that there 
was an increase in the distribution of solution and 
the nutrients to the right and left ventricles when the 
coronary sinus was totally occluded. 32 We therefore 
developed a self-inflating three-tiered catheter. 
which is larger and longer than the existing retro- 
grade catheters, toprevent the reflux of cardioplegic 
solution delivered in the retrograde fashion back 
into the atrium; in addition, it blocks the posterior 
descending vein so that cardioplegic solution does 
not re turn into the right atrium by a retrograde steal 
via the posterior descending vein (Fig. 2). 
Finally, delayed sternal closure was used in three 
patients to allow immediate postoperative swelling 
of the acutely failing heart after CABG in patients 
with an impaired edematous left ventricle. The 
sternum was closed on the second or third day and 
any serious infections were avoided by bringing up 
the omentum from the abdomen during the sternal 
closure. Table VI summarizes the costs and compli- 
cations of all adjuncts used. 
Conclusion. The cases of 111 consecutive pa- 
tients who underwent CABG during a 4-year period 
with a mean EF of 27.9% _ 5.4% were prospectively 
analyzed. Selection of patients included left main 
coronary artery disease, availability of two or more 
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major coronaries that would accept bypass grafts, 
and elective operation status; patients without an- 
gina who had viable myocardium demonstrated by
stress SPECT thallium testing or esophageal dobut- 
amine stress echocardiographic examination were 
included. The mortality rate of 1.8% was achieved, 
we believe, by the use of eight adjunctive therapies 
including four metabolic components (GIK, T3, 
aspartate/glutamate, and warm-cold-warm/ante- 
grade-retrograde-antegrade c rdioplegia) and four 
mechanical components (IABP, ultrafiltration, a 
new occlusive retrograde catheter, and, occasionally, 
delayed sternal closure). Patients with an EF be- 
tween 10% and 35% are unique in the spectrum of 
patients undergoing CABG, but with careful selec- 
tion and integrated preoperative and postoperative 
treatment, excellent postoperative mortality rates 
can be expected (Table VII). 
Sam Merrill, PhD, Wilkes University, Wilkes-Barre, 
Pa., was the consultant statistician for this study. 
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Discussion 
Dr. Joseph S. Carey (Torrance, Calif.). I would like to 
congratulate the authors on their great results in this 
group of patients with difficult conditions. Clearly atten- 
tion to detail is the most important aspect of getting ood 
results in patients at poor risk. In reviewing the manu- 
script and comparing this series with our own, several 
questions came up. 
During the same period we had 1309 patients who 
underwent isolated CABG and 163 of them had poor 
ventricular function defined as an EF less than 35%. This 
would be 12.5% of the patients as compared with the 
current report in which there were 111 of 1913 or 5.8% 
with poor ventricular function. In the current series only 
three patients were undergoing repeat CABG and 10% 
underwent the operation on an emergency basis. In our 
group 16% were in cardiogenic shock and 25% were 
undergoing repeat CABG. Not including patients in these 
two groups, we had four deaths in 104 patients, two of 
which were in the older age group. This is a similar 
mortality rate to that reported by Dr. Cimochowski, and 
we did not use most of the adjuncts that he has described. 
My questions mainly concern the impact of selection, 
referral patterns, and geographic location on the results. 
In California we have noted that there is a significant 
difference in the patient population as compared with the 
national database in that we have more repeat operations 
and more emergencies in California and also a higher 
overall risk profile. It has also been reported that the risk 
profile of patients in managed-care programs i  lower than 
that of the population at large. In our geographically 
isolated area, we have two hospitals that are doing cardiac 
operations and one of them has a consistently higher 
predicted, as well as observed, mortality. This is primarily 
because fewer managed-care patients are admitted to that 
hospital and more acutely ill patients and patients needing 
emergency operations are admitted to the other hospital. 
My first question is this: how are these differences in 
patient population explained and were some of the pa- 
tients with shock or repeat operations eliminated from 
this analysis, or were simply fewer sick patients referred? 
Dr. Cimochowski. No patients were eliminated. Actu- 
ally, during the past 6 years only 12 of our own patients 
from about 3000 have been reoperated on. We do have a 
rather locked-in referral base because we are the only 
heart program in a county of about 500,000 people. I
cannot account for the difference in repeat cases other 
than we are not seeing them in our population very much. 
I think it is an important issue, though. I looked at the STS 
database and asked them to eliminate repeat cases and 
their mortality rate was still 6.7%, which is considerable. I 
would not hesitate to do a repeat operation in a patient 
with poor ventricular function, but I think if one is 
attempting a repeat operation in a patient with an EF less 
than 20% there should probably be a cardiac transplant 
available or a major cardiac assist program. Lastly, we 
have little managed care in our area, and maybe that 
accounts for the difference between California and us. 
Dr. Carey. I do think that many of the authors' methods 
are innovative and worthy of note, particularly the evalu- 
ation of hemodynamics after induction of anesthesia and 
the insertion of the balloon pump in a patient who has a 
low cardiac output before bypass. Also, the early perfu- 
sion of the right graft is a good idea. I think the liberal use 
of inotropic agents before and after operation and ultra- 
filtration, like all of the other things, are quite important. 
It is also notable that the authors used so many internal 
thoracic artery grafts. Overall, I would say the study 
clearly shows that the careful management of these diffi- 
cult cases really boils down to carefully controlling all 
aspects of the care, and the value of each specific adjunct 
that is used is difficult and probably unnecessary to prove. 
Clearly just meticulously taking care of these patients with 
good clinical protocols is the most important hing. The 
only question I have regarding the method would be 
related to the expense of the T3 and that has more or less 
been answered. My final question would be whether the 
authors have looked at the late EF results: have any of 
these patients hown improved EFs? 
Dr. Cimochowski. No, we have not gotten late results 
yet, but we are in the process of doing so. We are also 
going to do quality-of-life studies on these patients as well, 
that is, look at long-term survival and at the EF results. 
I think we do have great influence over the anesthesia 
department, and so when a patient is brought to the 
operating room, as you point out, with a cardiac index of 
1.5 L/m 2, the anesthesiologists immediately start adminis- 
tration of these drugs and they progress up the ladder (in 
fact, a femoral ine is placed in all patients), and we will 
then proceed right to placement of a balloon pump before 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 113, Number 4 
Cimochowski, Harostock, Foldes 6 6 5 
starting the procedure. We do like to start with an index 
greater than 2.0 L/m 2. If these low EF procedures are 
started with an index less than 2.0 L/m 2, the outcome is 
oftentimes not very good. 
I would like to emphasize the use of the internal 
thoracic artery, too. As you know, Dr. Grover and his 
group have noted repeatedly that in emergencies, myocar- 
dial infarctions, and other circumstances, patients with an 
internal thoracic artery seem to do better. We use the 
internal thoracic artery about 83% percent of the time in 
these patients and that point has been confirmed. 
Dr. Harold Lazar (Boston, Mass.). There are really no 
controls in this series, so it is kind of difficult o put these 
good results in some perspective. My first question is 
whether the authors can tell us what their mortality rate 
was in the preceding years in this group of patients. 
Dr. Cimoehowski. I cannot because I have only been at 
this institution since 1990. I can tell you that we had very 
good cases, it seems, the first two years. In 1993, we had 20 
cases of poor ventricular function and in 1994 we had 30 
such cases. In 1995, we had 42, so we have doubled the 
incidence in the most recent 2 years. I think before that 
the number of patients in this category was too small to be 
critically examined. 
Dr. Lazar. So in essence you really could have had an 
operative mortality rate of 3%, but you do not know the 
answer to that. 
My second question is that in 50% of the patients the 
authors ay that there was no angina present. I was curious 
as to what the indications were for operation in this group. 
Dr. Cimochowski. Twenty-nine percent of the patients 
had congestive heart failure as the presenting feature. 
Others had acute myocardial infarctions and no longer 
had pain, that is, they had a myocardial infarction but 
after catheterization had no angina. I cannot break down 
the indications for operation any further than that, but I 
personally reviewed these charts and there were only 50% 
who reported angina. 
Dr. Lazar. That leads me to my final two questions. If
these patients do not have any pain and they do have low 
EFs, then obviously long-term follow-up and long-term 
results are important. I think the question was raised 
about whether the authors saw any improvement in EF. 
Can they tell us whether these patients had any improve- 
ment, not only in long-term survival, but also in New York 
Heart Association or Canadian classification? 
Dr. Cimochowski. We are working on compiling the 
long-term results at present. 
Dr, Edward Verrier (Seattle, Wash.). I am fairly con- 
cerned, because I think that to take this shotgun approach 
and take a huge number of adjuncts that have potential 
benefit and apply them to a population in which the 
physiologic processes are not really delineated isa mistake 
and dangerous. An IABP has a definite set of risks that are 
associated with it. The major series from Massachusetts 
General showed a 21% incidence of significant complica- 
tions from balloons. The inappropriate use of T 3 also has 
potential dangers. When we deal with these sick hearts 
with low EF, there are a myriad of problems that are going 
on physiologically. 
There is a group that has hibernating myocardium, that 
reset their thermostats: their biochemical machinery is 
different. They probably do not require much protection 
and they will get some recovery of function. There are 
many patients I have operated on who had EFs before 
operation of 1.4% who left the operating room receiving 
hardly any inotropes with an index of 3 because we did the 
positron emission tomographic scans or other studies 
before operation and knew that there was some predict- 
able recovery because they had a chronic ischemic state 
and had reset their thermostat. 
To take the authors' approach and just use all of the 
adjuncts available I think is not cost effective, certainly. It 
may not be the safest hing as well because complications 
occur from a variety of the interventions and in a lot of the 
instances we do not even understand how they work. They 
may work in one situation because the metabolic machin- 
ery is being enhanced and that is going to upregulate it. I 
would take caution, because I think that many of us 
achieve similar results to those of the authors without 
using all of these adjuncts. I have not perfused a right 
coronary graft in the past 5 years with my retrograde 
technique and I have never had a patient who could not be 
weaned from cardiopulmonary b pass because of right 
ventricular disease. That may be my particular experience, 
but I think it behooves us to analyze from a physiologic 
standpoint what we do as surgeons. We are physiologists, 
as well as simply people who are technicians who take a 
number of techniques that we have available and apply 
them. 
Dr. Cimoehowski. The physiologic basis for all these 
adjuncts is clearly explained in our paper. I think the word 
dangerous for our method is a little strong. We certainly 
think as you do that there are inappropriate uses of the 
balloon pump, but with this group I do not think the 20% 
preoperative and 9% intraoperative placement rate was 
inappropriate or excessive. I understand your conclusion 
concerning the use of multiple adjuncts. They were insti- 
tuted to address the multitude of abnormal physiologic 
conditions in this highly selective group of patients. There 
is not a single randomized study anywhere in the literature 
with respect o severe left ventricular dysfunction, so I 
think we are certainly in good company. 
Dr. Steven Gundry (Loma Linda, Calif.). I hate to 
belabor the point but I agree with the last two discussants. 
First of all, Dr. Lazar pointed out that the authors really 
do not have a control group. Well, in fact they do have a 
control group and each patient is his or her own control. 
At Loma Linda several years ago we decided that if a 
patient is receiving no inotropic support and breathing on 
his or her own when brought into the operating room, 
then if everything is done right he or she ought to leave 
the operating room receiving no inotropic support and 
breathing on his or her own, and so that patient is his or 
her own control. 
Now, as we reported at the Pacific Coast Surgical 
Association meeting last year, we looked at 36 consecutive 
patients with EFs of less than or equal to 15% who 
underwent warm heart operations with the use of contin- 
uous retrograde cardioplegia with a simple balloon cath- 
eter that was manually inflated. None of these patients 
required an IABP. Only 10% of them required any 
inotropic support. There were no perioperative deaths, 
and the average time to discharge from the hospital was 6 
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postoperative days. That was compared with how they 
walked in: receiving no inotropes and breathing on their 
own. I would submit that the additional cost that the 
authors add to the patient's hospital bill is actually what 
we charge to do the entire operation in California. I 
wonder whether they have looked specifically at what 
these modifications do that is so important in achieving 
the results that others of us achieve with none of these 
modifications. 
Dr. Cimoehowski. We had a large experience with 
continuous warm retrograde cardioplegia nd we were 
unhappy with it, more so in valve operations than CABG. 
Specifically, we had three cases of stone heart because 
either the cardioplegic solution was not adequately deliv- 
ered because of a perfusion problem or because of a 
retrograde catheter problem. I personally do not think 
that warm continuous cardioplegia is a safe method for 
coronary bypass operations and even less so for valve 
operations. The STS database, which covers 26,000 pa- 
tients, showed a mortality rate of 7.6% with an EF 
between 10% and 30%. These 26,000 patients were oper- 
ated on by American surgeons in the United States. I
think it is a fair assumption to say that the mortality rate 
is not 1% to 2% and that overall the average surgeon 
operating on this group of patients achieves a rate of 7% 
to 8%. Our mortality rate in all patients undergoing 
CABG for the past 2 years was 1.6% and 1.4%, respec- 
tively, but the mortality rate in the low EF group for 
patients undergoing CABG was still higher at 1.8%. 
I would note that unlike California, which does not 
publish cardiac operative outcomes, Pennsylvania does. In 
addition, cost of operation is published and in the most 
recent publication we were the third least expensive 
program in the state of Pennsylvania and 3 years ago we 
were the only program in the state that cost less than the 
year before. I believe we are as cost conscious as anybody 
else. The only adjunct hat is a luxury is the T3, and I guess 
time will prove whether that is worthwhile. 
Dr. James Edgerton (Racine, Wis.). I hesitate to speak 
after the last couple discussants, but I will commend Dr. 
Cimochowski for bearing the barbs and trying to bring 
some objectivity to what many people are anecdotally 
doing. I am continually impressed, when I go to these 
meetings and talk in the hallways, by how many people are 
using T 3. I have one or two quick questions about that. 
We also have all of our data published. We have one of 
the lowest average costs per case in the state of Wisconsin 
and among the lowest mortality rates in Wisconsin and 
have been using T3. Initially we used it only for salvage 
cases in which the patient was obviously going to die in the 
operating room. We were impressed that with it some of 
the patients were able to be weaned from cardiopulmo- 
nary bypass. Since that time, we have been using T 3 in our 
patients with EFs less than 15%. We use a protocol a little 
bit different from the authors', but similar. We give a 16 
tzg bolus when the clamp comes off or when the last distal 
anastomosis i  done and then administer a rapidly taper- 
ing infusion. We are doing increasing numbers of these 
operations with no crossclamp, no arrest, and occasionally 
no pump. I would wonder, incidentally, whether the 
authors are going to any of those techniques. We notice 
differently from the authors that the administration of T 3 
drops the aftertoad so considerably ow that we are not 
able to keep nitroprusside or nitroglycerin effective in 
those patients. It is not at all uncommon to see values of 
systemic vascular resistance of 400 to 500. I wonder 
whether the authors have encountered that. 
Dr. Cimochowski. To answer somebody else's question 
about what I think is the most important adjunct, I think 
GIK and T 3 are most important for just the reasons you 
elicited. I did not have enough time to show the systemic 
vascular esistance data, but our values of systemic vascu- 
lar resistance consistently decrease from the time the 
patient is brought o the operating room from about 1000 
or 1200 to the 800 dyne range, and they stay there all 
during the immediate postoperative p riod. We like that. 
I think one of the problems is our anesthesiologists. Five 
of the six trained at different major universities for an 
extra year of cardiac anesthesia, nd every, single one of 
them was taught to discontinue bypass with a mean 
arterial pressure of 90 to 100 mm Hg and concomitant 
higher values of systemic vascular esistance. We do not 
do that. We accept a mean arterial pressure that is much 
less and that is one of the reasons we like T3, because 
afterload in these patients is smoothly, effectively, and 
continuously controlled from induction of anesthesia 
through the next day and a few days later. Systemic 
unloading throughout the perioperative period is a good 
point to emphasize. 
Dr. Edgerton. As a final comment, we have noted that 
our use of IABPs after we have started our intravenous T3 
protocol in patients with EFs less than 15% is almost zero. 
We use very few IABPs. I wonder whether they are 
needed preoperatively. We also looked at the hospital 
charge for the patient. In our medical center (where there 
is a setup fee for the balloon, a charge for the balloon, and 
an hourly monitoring fee for the balloon), the cost of the 
T3 is considerably ess than 24 hours of balloon pumping. 
Dr. Cimochowski. During the past year we had the 
greatest number of cases of poor ventricular function, and 
yet our use of the IABP went down. As we gain more 
confidence in our metabolic adjuncts, we will most likely 
use the IABP less and use the metabolic adjuncts more. 
